ProCAID: A randomized double-blind phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castration-resistant prostate cancer (mCRPC).

Simon J. Crabb,Gareth Griffiths,Ellice Marwood,Denise Dunkley,Nichola Downs,Karen Martin,Michelle Light,Josh Northey,Amy Whitehead,Emily C. Shaw,Alison J. Birtle,Amit Bahl,Tony Elliott,Charlotte Westbury,Santhanam Sundar,Angus Robinson,Satinder Jagdev,Satish Kumar,Vincent Khoo,Robert Jones

ProCAID: A randomized double-blind phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castration-resistant prostate cancer (mCRPC).

2020

5520Background: DP extends survival in mCRPC, but clinical benefit is modest. PI3K/AKT/PTEN pathway activation is common in mCRPC contributing to disease progression and DP resistance. C is a pan-A...

Keywords:

Oncology
double blind
Chemotherapy
Pathology
Clinical trial
castration resistant
Prednisolone
Prostate cancer
Internal medicine
Docetaxel
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations